EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study

Congyi Xie iD, Jinzhan Chen, Shuwen Yang, Feiyang Ye, Zhenyang Lin, Yijiao Xu, Yimin Yang, Lin Tong

The Clinical Respiratory Journal · 2025

DOI: 10.1111/crj.70051 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Clinical Respiratory Journal, 2025. Verfasst von Congyi Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, People's Republic of China. Hauptthemen laut MEDLINE: Lung Neoplasms, Indoles, Quinolines. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Provincial Department of Science and Technology, National Natural Science Foundation of China, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Anlotinib is widely used in the treatment of lung cancer. However, there remains a lack of predictive biomarkers to effectively gauge the response to anlotinib therapy. We conducted a retrospective study to preliminarily explore potential risk factors that might predict outcomes in lung cancer patients undergoing anlotinib treatment. Patients and Methods We retrospectively analyzed lung cancer patients treated with anlotinib at our hospital between 1 June 2018 and 1 June 2021. Data were gathered from electronic medical records. Demographic and clinical characteristics of patients, progression‐free survival (PFS), and overall survival (OS) were described. Predictive factors related to treatment efficacy were preliminarily analyzed using Cox regression and Kaplan–Meier survival analyses.

Results

After adjusting for potential confounders, clinical stage IV (hazard ratio [HR] = 2.52, 95% confidence interval [CI], 1.09–5.82, p = 0.0311), N‐terminal fragment brain natriuretic peptides (NT‐pro‐BNP) > 300 pg/mL (HR = 2.54, 95% CI, 1.17–5.52, p = 0.0183), and neuron‐specific enolase (NSE) > 16.3 ng/mL (HR = 1.70, 95% CI, 1.03–2.81, p = 0.0389) were associated with shorter OS, whereas age (HR = 0.96, 95% CI, 0.94–0.99, p = 0.0055) was associated with a longer PFS in fully adjusted model. Kaplan–Meier analyses of cumulative risk factors (clinical stage IV, NT‐pro‐BNP > 300 pg/mL, and NSE > 16.3 ng/mL) indicated that patients with a greater number of coexisting risk factors had significantly shorter OS ( p < 0.0001).

Conclusion

Clinical stage IV, NT‐pro‐BNP level, and NSE level were identified as independent prognostic factors for lung cancer patients undergoing anlotinib treatment. Patients with multiple high‐risk factors may derive limited benefit from anlotinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsIndolesQuinolinesHumansMaleFemaleRetrospective StudiesMiddle AgedRisk FactorsPrognosisAgedPeptide FragmentsNeoplasm StagingAdultPhosphopyruvate HydrataseBiomarkers, TumorKaplan-Meier EstimateNatriuretic Peptide, Brain

Stichwörter der Autor:innen

anlotiniblung cancersurvival

Substanzen

IndolesanlotinibQuinolinesPeptide FragmentsPhosphopyruvate HydrataseBiomarkers, Tumorpro-brain natriuretic peptide (1-76)Natriuretic Peptide, Brain

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, People's Republic of China.
  • Xiamen Clinical Research Center for Cancer Therapy, Xiamen, Fujian, People's Republic of China.
  • College of Computer and Data Science, Fuzhou University, Fuzhou, Fujian, People's Republic of China.
  • Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, People's Republic of China.
  • Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
  • Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

ORCID-Profile: Congyi Xie

Förderung

  • Fujian Provincial Department of Science and Technology
  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Xie, C., Chen, J., Yang, S., Ye, F., Lin, Z., Xu, Y., Yang, Y., & Tong, L. (2025). Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70051

Vancouver

Xie C, Chen J, Yang S, Ye F, Lin Z, Xu Y, et al. Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study. The Clinical Respiratory Journal. 2025. doi:10.1111/crj.70051

BibTeX
@article{Xie2025,
  author = {Xie, Congyi and Chen, Jinzhan and Yang, Shuwen and Ye, Feiyang and Lin, Zhenyang and Xu, Yijiao and Yang, Yimin and Tong, Lin},
  title = {Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study},
  journal = {The Clinical Respiratory Journal},
  year = {2025},
  doi = {10.1111/crj.70051}
}
Kostenlos starten →